Farydak
Product Images NDC 73116-100

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Farydak (NDC 73116-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Secura Bio, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (10mg Secura Carton V1)

The packaging label for FARYDAK (panobinostat) capsules by Secura Bio, Inc. displays a 10 mg strength, equivalent to 12.58 mg panobinostat lactate. The box contains 6 capsules. Instructions emphasize swallowing whole with water and storing the blister pack in the original carton to protect from light. Manufacturer details include Novartis Farmacéutica SA, Spain, and Secura Bio, Inc. as distributor in Las Vegas, Nevada.*

FDA Label Image

Principal Display Panel (15mg Secura Carton V1)

Box packaging label for FARYDAK capsules (panobinostat) 15 mg, distributed by Secura Bio, Inc. The package contains 6 capsules, each equivalent to 18.86 mg panobinostat lactate. The label includes handling instructions and manufacturer information for Novartis Farmacéutica SA, Spain.*

FDA Label Image

Principal Display Panel (20mg Secura Carton V1)

FARYDAK 20 mg (panobinostat) capsules label showing packaging for 6 capsules. The label includes the active ingredient panobinostat, equivalent to 25.15 mg panobinostat lactate, and directions including swallowing whole and storage guidance. Manufactured by Novartis Farmacéutica SA, Spain, and distributed by Secura Bio, Inc., Las Vegas, Nevada. Includes barcodes and medication guide instructions.*

FDA Label Image

Faridak Chemical Structure (Farydak 01)

Chemical structure diagram of the active ingredient of FARYDAK, an FDA-registered drug product by Secura Bio, Inc. The structure includes multiple ring systems, amide and hydroxyl functional groups, characteristic of the compound's molecular arrangement.*

FDA Label Image

Figure 1 Progression-free Survival (mebmt Criteria): Kaplan Meier Plot (Farydak 02)

A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months for two groups: FARYDAK+BTZ+Dex and placebo+BTZ+Dex. The chart includes censoring times and a table listing the number of patients at risk at various time points up to 30 months. BTZ is defined as bortezomib and Dex as dexamethasone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.